Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.
Seung Hyun JungChoong-Kun LeeWoo Sun KwonSujin YunMinkyu JungHyo Song KimHyun Cheol ChungYeun-Jung ChungSun Young RhaPublished in: Yonsei medical journal (2023)
Our data indicate that the serial genetic alteration profiling of ctDNA is feasible to predict treatment response in HER2-positive GC patients in a minimally invasive manner. Practically, ctDNA profiles are useful not only for the molecular diagnosis of GC but also for the selection of GC patients with poor prognosis for systemic treatment (ClinicalTrials.gov identifier: NCT02901301).
Keyphrases
- poor prognosis
- minimally invasive
- end stage renal disease
- long non coding rna
- ejection fraction
- chronic kidney disease
- squamous cell carcinoma
- newly diagnosed
- gas chromatography
- prognostic factors
- small cell lung cancer
- peritoneal dialysis
- electronic health record
- single cell
- type diabetes
- locally advanced
- big data
- high resolution
- single molecule
- insulin resistance
- deep learning
- weight loss
- simultaneous determination
- glycemic control